BioArctic AB (publ) (Nasdaq Stockholm: BIOA B), a Swedish research-based biopharma company, announced yesterday that it has started the first clinical study with ABBV-0805 in the United States.
US-based biopharmaceutical company, AbbVie, is responsible for the clinical development of ABBV-0805. The Phase one study in healthy volunteers will investigate the safety and tolerability of the product. It is claimed to be the most advanced within the portfolio of alpha-synuclein targeting antibodies in-licensed by AbbVie from BioArctic in December 2018. The antibody is being evaluated as a disease modifying treatment for Parkinson's disease. It is a result of a strategic research alliance between BioArctic and AbbVie focused on the development of a potential immunotherapy for Parkinson's disease.
Gunilla Osswald, PhD, CEO, BioArctic, said, 'It is gratifying that our partner AbbVie has started the first clinical trial, a Phase 1 study, with ABBV-0805. We are now looking forward to ABBV-0805 moving forward in the clinical program and developing into a therapy with the potential to provide meaningful advances for patients with Parkinson's disease.'
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study